Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | RAB9A | P51151 | 4/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | CASP3 | P42574 | 1/20 | 0.70 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.70 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6117859 | 0.88 | MEN1 (1.00) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL7662705 | 0.84 | KMT2A (0.79) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL29620661 | 0.82 | KMT2A (1.00) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL3246467 | 0.82 | KMT2A (1.00) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL27944077 | 0.82 | MEN1 (0.87) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL18817919 | 0.79 | MEN1 (0.66) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL10997076 | 0.78 | NPC1 (0.92) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL14452530 | 0.78 | KMT2A (0.62) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL17199123 | 0.78 | PDE10A (0.63) | NPC1KMT2ARAB9AMEN1KDM4E | |
| SCHEMBL16382924 | 0.78 | KMT2A (0.62) | NPC1KMT2ARAB9AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| EP-1986633-B1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORP PLC (GB) | 2014-07-30 | — | — | EP | disclosed |
| EP-1986633-B1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORP PLC (GB) | 2014-07-30 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| CN-101678107-A | Pharmaceutical composition for treating Duchenne muscular dystrophy | SUMMIT CORP PLC | 2010-03-24 | — | — | CN | disclosed |
| CN-101420950-A | Treatment of Duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPC1 2477/4885KMT2A 3778/4885RAB9A 3748/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | NPC1 2477/4885KMT2A 3778/4885RAB9A 3748/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885KMT2A 2571/4885RAB9A 4325/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885KMT2A 2571/4885RAB9A 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.